Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Shorter are mad right now.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(303)
•••
Comment by Dude51on Jul 22, 2021 12:39am
162 Views
Post# 33586336

RE:RE:RE:RE:Shorter are mad right now.

RE:RE:RE:RE:Shorter are mad right now.Kaiser here is some advise, google Andrew Salzman and if you come up with something Nefarious or Slimy as in your world, lettuce know, eh? We would all be extremely interested in your find. This CLAS stock is no SONA. This has got potential. Read young man read, check out Robert Farrell while you are at it and check out how many PHD’s with extreme experience and knowledge many of whom have penned books and papers and they now work for CLAS. This company is the center/leader in the field of the Nitric Oxide deployment. Check out R-107 Report back to us later after jumping on board. Do you really think anyone would dare try to short this stock with the potential come Friday. Check em out, trust me. No you mark this post. lol back at you.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities